Federal contract award

75F40125C00085

BAA-FY25C3BP2 - PHARMACODYNAMICS OF DAPTOMYCIN AGAINST ENTEROCOCCUS FAECIUMAND ENTEROCOCCUS FAECALIS IN THE MURINE THIGH INFECTION MODEL.

Research the contractorView USAspending sourceSave to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

FieldReported value
AgencyDepartment of Health and Human Services
OfficeFDA OFFICE OF ACQ GRANT SVCS
NAICS541714 — Research and Development in Biotechnology (except Nanobiotechnology)
PSCAN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH
Parent award / vehicleNot reported
Set-asideNO SET ASIDE USED.
Pricing typeCOST NO FEE
Obligations$325.0K
Current contract value$325.0K
Potential contract value / ceiling$325.0K
Start dateSep 22, 2025
Current end dateSep 29, 2026
Potential end dateSep 29, 2026
Latest award activityApr 21, 2026
Source loadedSep 26, 2026

Funding and modification history

Showing the latest 2 of 2 loaded transactions. Negative values are deobligations.

DateModificationObligation changeDescription
Apr 21, 2026P00001$0MOD P00001 BAA-FY25C3BP2 - PHARMACODYNAMICS OF DAPTOMYCIN AGAINST ENTEROCOCCUS FAECIUMAND ENTEROCOCCUS FAECALIS IN THE MURINE THIGH INFECTION MODEL.
Sep 22, 20250$325.0KBAA-FY25C3BP2 - PHARMACODYNAMICS OF DAPTOMYCIN AGAINST ENTEROCOCCUS FAECIUMAND ENTEROCOCCUS FAECALIS IN THE MURINE THIGH INFECTION MODEL.

Research next steps

  1. Check the stated set-aside against the solicitation and current certifications.
  2. Review the award scope and buyer evidence before making a bid/no-bid decision.